YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today ...

Vasa Therapeutics Granted FDA Fast Track Designation for VS-041, a Novel Investigational Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Vasa Therapeutics ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and ...

Celcuity Inc.: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
TipRanks on MSN

Dermata Therapeutics Ends License Agreement with Villani

An update from Dermata Therapeutics ( ($DRMA) ) is now available. On November 17, 2025, Dermata Therapeutics announced the termination of its ...
Targeted Oncology

Novel TROP2-Targeting ADC Gains FDA Orphan Drug Status in Cholangiocarcinoma

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...
Labiotech.eu

On the fast track to the clinic: early decisions in drug development

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
WJCL on MSN

Murder suspect on the run captured on I-95 in Coastal Georgia

Police in Coastal Georgia arrested a man after a traffic stop on Interstate 95 led to the discovery of a stolen SUV and his ...

Palatin Technologies, Inc. (AMEX:PTN) Q1 2026 Earnings Call Transcript

Q1 2026 Earnings Call Transcript November 13, 2025 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2026 ...
TMCnet

Vincere Biosciences Awarded $5 Million from The Michael J. Fox Foundation to Advance Parkinson's Therapeutic Toward Clinical Trials

Awarded grant from The Michael J. Fox Foundation will support the advancement of Vincere's USP30 inhibitors and accompanying biomarkers for Parkinson's disease through IND-enabling studies that will ...

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement

The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in ...

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock

On November 13, 2025, effective November 14, 2025 the Securities and Exchange Commission (“Commission”), in Administrative Proceeding File No. 3-22541, in Release No. 104178 issued an Order Making ...